comparemela.com

Latest Breaking News On - Global immunology therapeutic area head - Page 1 : comparemela.com

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.

Jersey
David-lee
Johnson
None-of-cilag-holding
Janssen-research-development
Janssen-biotech-inc
Cilag-holding
Numab-therapeutics
Global-immunology-therapeutic-area-head
Johnson-innovative
Candice-long
Worldwide-vice-president

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.

David-lee
Johnson
Proteologix-inc
Global-immunology-therapeutic-area-head
Johnson-innovative
Shockwave-medical

vimarsana © 2020. All Rights Reserved.